NeoGenomics Inc (NEO)
15.39
+0.03
(+0.20%)
USD |
NASDAQ |
Nov 21, 16:00
15.38
0.00 (0.00%)
After-Hours: 20:00
NeoGenomics Enterprise Value: 2.128B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.128B |
| November 20, 2024 | 2.124B |
| November 19, 2024 | 2.124B |
| November 18, 2024 | 2.079B |
| November 15, 2024 | 2.083B |
| November 14, 2024 | 2.179B |
| November 13, 2024 | 2.262B |
| November 12, 2024 | 2.249B |
| November 11, 2024 | 2.251B |
| November 08, 2024 | 2.177B |
| November 07, 2024 | 2.183B |
| November 06, 2024 | 2.137B |
| November 05, 2024 | 2.069B |
| November 04, 2024 | 1.968B |
| November 01, 2024 | 1.950B |
| October 31, 2024 | 1.893B |
| October 30, 2024 | 1.880B |
| October 29, 2024 | 1.884B |
| October 28, 2024 | 1.879B |
| October 25, 2024 | 1.826B |
| October 24, 2024 | 1.824B |
| October 23, 2024 | 1.826B |
| October 22, 2024 | 1.846B |
| October 21, 2024 | 1.834B |
| October 18, 2024 | 1.889B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.881B |
| October 16, 2024 | 1.924B |
| October 15, 2024 | 1.949B |
| October 14, 2024 | 1.921B |
| October 11, 2024 | 1.885B |
| October 10, 2024 | 1.887B |
| October 09, 2024 | 1.817B |
| October 08, 2024 | 1.874B |
| October 07, 2024 | 1.917B |
| October 04, 2024 | 1.938B |
| October 03, 2024 | 1.961B |
| October 02, 2024 | 1.989B |
| October 01, 2024 | 1.921B |
| September 30, 2024 | 2.041B |
| September 27, 2024 | 2.010B |
| September 26, 2024 | 2.028B |
| September 25, 2024 | 2.069B |
| September 24, 2024 | 2.177B |
| September 23, 2024 | 2.177B |
| September 20, 2024 | 2.238B |
| September 19, 2024 | 2.264B |
| September 18, 2024 | 2.223B |
| September 17, 2024 | 2.239B |
| September 16, 2024 | 2.245B |
| September 13, 2024 | 2.254B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
907.39M
Minimum
Oct 21 2022
6.864B
Maximum
Feb 12 2021
2.981B
Average
2.363B
Median
Nov 14 2023
Enterprise Value Benchmarks
| Bruker Corp | 10.71B |
| Henry Schein Inc | 13.19B |
| Karyopharm Therapeutics Inc | 154.51M |
| Apellis Pharmaceuticals Inc | 3.507B |
| Beam Therapeutics Inc | 1.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.70M |
| Revenue (Quarterly) | 167.82M |
| Total Expenses (Quarterly) | 188.01M |
| EPS Diluted (Quarterly) | -0.14 |
| Gross Profit Margin (Quarterly) | 44.62% |
| Profit Margin (Quarterly) | -10.55% |
| Earnings Yield | -3.96% |
| Normalized Earnings Yield | -3.656 |